Hikma Satisfies Warning Letter Complaints, Reopens U.S. Plant
This article was originally published in PharmAsia News
Executive Summary
Hikma Pharmaceuticals said it has corrected the problems in its New Jersey plant that prompted a U.S. FDA warning letter and is set to begin a gradual reintroduction of its drugs to the U.S. market after a two-year hiatus.